Search Results

There are 5383 results for: content related to: Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis

  1. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease

    Intervention Review

    The Cochrane Library

    Reena Khanna, Jan C Preiss, John K MacDonald and Antje Timmer

    Published Online : 5 MAY 2015, DOI: 10.1002/14651858.CD007572.pub2

  2. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years

    British Journal of Dermatology

    Volume 166, Issue 4, April 2012, Pages: 861–872, A.B. Kimball, K.B. Gordon, S. Fakharzadeh, N. Yeilding, P.O. Szapary, B. Schenkel, C. Guzzo, S. Li and K.A. Papp

    Article first published online : 27 MAR 2012, DOI: 10.1111/j.1365-2133.2012.10901.x

  3. Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters

    The Journal of Dermatology

    Volume 37, Issue 5, May 2010, Pages: 413–425, Manjula REDDY, Gisela TORRES, Thomas McCORMICK, Colleen MARANO, Kevin COOPER, Newman YEILDING, Yuhua WANG, Charles PENDLEY, Uma PRABHAKAR, Jackson WONG, Cuc DAVIS, Stephen XU and Carrie BRODMERKEL

    Article first published online : 9 APR 2010, DOI: 10.1111/j.1346-8138.2010.00802.x

  4. You have free access to this content
    Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial

    The Journal of Dermatology

    Volume 39, Issue 3, March 2012, Pages: 242–252, Atsuyuki IGARASHI, Takeshi KATO, Mai KATO, Michael SONG, Hidemi NAKAGAWA and THE JAPANESE USTEKINUMAB STUDY GROUP

    Article first published online : 29 SEP 2011, DOI: 10.1111/j.1346-8138.2011.01347.x

  5. Ustekinumab: Lessons Learned from Targeting Interleukin-12/23p40 in Immune-Mediated Diseases

    Annals of the New York Academy of Sciences

    Volume 1182, Issue 1, December 2009, Pages: 97–110, Michael Elliott, Jacqueline Benson, Marion Blank, Carrie Brodmerkel, Daniel Baker, Kristin Ruley Sharples and Philippe Szapary

    Article first published online : 10 DEC 2009, DOI: 10.1111/j.1749-6632.2009.05070.x

  6. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study

    Journal of the European Academy of Dermatology and Venereology

    Volume 27, Issue 12, December 2013, Pages: 1535–1545, A.B. Kimball, K.A. Papp, Y. Wasfi, D. Chan, R. Bissonnette, H. Sofen, N. Yeilding, S. Li, P. Szapary, K.B. Gordon and on behalf of the PHOENIX 1 investigators

    Article first published online : 20 DEC 2012, DOI: 10.1111/jdv.12046

  7. Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis

    Clinical and Experimental Dermatology

    Volume 39, Issue 6, August 2014, Pages: 696–707, Y. Meng, L. Dongmei, P. Yanbin, F. Jinju, T. Meile, L. Binzhu, H. Xiao, T. Ping and L. Jianmin

    Article first published online : 14 JUL 2014, DOI: 10.1111/ced.12390

  8. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial

    British Journal of Dermatology

    Volume 162, Issue 1, January 2010, Pages: 137–146, M. Lebwohl, K. Papp, C. Han, B. Schenkel, N. Yeilding, Y. Wang and G.G. Krueger

    Article first published online : 9 NOV 2009, DOI: 10.1111/j.1365-2133.2009.09491.x

  9. Population-Based Exposure-Efficacy Modeling of Ustekinumab in Patients With Moderate to Severe Plaque Psoriasis

    The Journal of Clinical Pharmacology

    Volume 50, Issue 3, March 2010, Pages: 257–267, Dr Honghui Zhou, Dr Chuanpu Hu, Dr Yaowei Zhu, Dr Ming Lu, Dr Sam Liao, Dr Newman Yeilding and Dr Hugh M. Davis

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270009343695

  10. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-il-12/23p40 monoclonal antibody, during pregnancy and lactation

    Birth Defects Research Part B: Developmental and Reproductive Toxicology

    Volume 89, Issue 5, October 2010, Pages: 351–363, Pauline L. Martin, Clifford Sachs, Noritaka Imai, Hideshi Tsusaki, Satoru Oneda, Qun Jiao and George Treacy

    Article first published online : 10 JUN 2010, DOI: 10.1002/bdrb.20250

  11. Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points

    Journal of the European Academy of Dermatology and Venereology

    Volume 28, Issue 12, December 2014, Pages: 1633–1653, L. Puig, A. López, E. Vilarrasa and I. García

    Article first published online : 19 AUG 2013, DOI: 10.1111/jdv.12238

  12. Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: Results from a randomized, double-blind, placebo-controlled phase 2 / 3 trial

    The Journal of Dermatology

    Volume 39, Issue 9, September 2012, Pages: 761–769, Hidemi NAKAGAWA, Brad SCHENKEL, Mai KATO, Takeshi KATO, Atsuyuki IGARASHI and The Japanese Ustekinumab Study Group

    Article first published online : 12 MAR 2012, DOI: 10.1111/j.1346-8138.2012.01521.x

  13. Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis

    The Journal of Clinical Pharmacology

    Volume 49, Issue 2, February 2009, Pages: 162–175, Dr Yaowei Zhu, Dr Chuanpu Hu, Dr Ming Lu, Dr Sam Liao, Dr Joseph C. Marini, Dr Jennifer Yohrling, Dr Newman Yeilding, Dr Hugh M. Davis and Dr Honghui Zhou

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270008329556

  14. ‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network

    British Journal of Dermatology

    Volume 171, Issue 5, November 2014, Pages: 1189–1196, J.M.P.A. van den Reek, J. Zweegers, W. Kievit, M.E. Otero, P.P.M. van Lümig, R.J.B. Driessen, P.M. Ossenkoppele, M.D. Njoo, J.M. Mommers, M.I.A. Koetsier, W.P. Arnold, B.A.M. Sybrandy-Fleuren, A.L.A. Kuijpers, M.P.M. Andriessen, P.C.M. van de Kerkhof, M.M.B. Seyger and E.M.G.J. de Jong

    Article first published online : 3 OCT 2014, DOI: 10.1111/bjd.13087

  15. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C

    British Journal of Dermatology

    Volume 169, Issue 6, December 2013, Pages: 1295–1303, H.-Y. Chiu, C.-H. Chen, M.-S. Wu, Y.-P. Cheng and T.-F. Tsai

    Article first published online : 2 DEC 2013, DOI: 10.1111/bjd.12461

  16. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases

    International Journal of Dermatology

    Volume 54, Issue 10, October 2015, Pages: 1194–1198, Naomi Takahashi, Shinji Noda, Takashi Taniguchi and Makoto Adachi

    Article first published online : 27 MAY 2015, DOI: 10.1111/ijd.12859

  17. Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials

    Journal of the European Academy of Dermatology and Venereology

    Volume 25, Issue 7, July 2011, Pages: 851–857, L. Guenther, C. Han, P. Szapary, B. Schenkel, Y. Poulin, M. Bourcier, J.P. Ortonne and H.L. Sofen

    Article first published online : 27 APR 2011, DOI: 10.1111/j.1468-3083.2011.04082.x

  18. You have full text access to this OnlineOpen article
    Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial

    Arthritis Care & Research

    Volume 67, Issue 12, December 2015, Pages: 1739–1749, Arthur Kavanaugh, Lluís Puig, Alice B. Gottlieb, Christopher Ritchlin, Shu Li, Yuhua Wang, Alan M. Mendelsohn, Michael Song, Yaowei Zhu, Proton Rahman, Iain B. McInnes and on behalf of the PSUMMIT 1 Study Group

    Article first published online : 24 NOV 2015, DOI: 10.1002/acr.22645

  19. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response

    British Journal of Dermatology

    Volume 168, Issue 5, May 2013, Pages: 990–998, E.M. Baerveldt, A.J. Onderdijk, D. Kurek, M. Kant, E.F. Florencia, A.S. Ijpma, P.J. van der Spek, J. Bastiaans, P.A. Jansen, J.W.J. van Kilsdonk, J.D. Laman and E.P. Prens

    Article first published online : 25 APR 2013, DOI: 10.1111/bjd.12175

  20. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives

    Annals of the New York Academy of Sciences

    Volume 1222, Issue 1, March 2011, Pages: 30–39, Newman Yeilding, Philippe Szapary, Carrie Brodmerkel, Jacqueline Benson, Michael Plotnick, Honghui Zhou, Kavitha Goyal, Brad Schenkel, Jill Giles-Komar, Mary Ann Mascelli and Cynthia Guzzo

    Article first published online : 22 MAR 2011, DOI: 10.1111/j.1749-6632.2011.05963.x